Boston Scientific Initiates Study Evaluating New Fully Resorbable Scaffold Technology

First Patients Enrolled in the FAST Feasibility Study

Jul 20, 2015, 09:00 ET from Boston Scientific

MARLBOROUGH, Mass., July 20, 2015 /PRNewswire/ -- Boston Scientific (NYSE: BSX) has initiated a study of the company's first fully resorbable drug-eluting scaffold system. The Fully Absorbable Scaffold Feasibility Study (FAST) is a prospective, single arm study designed to assess the safety and performance of this next generation scaffold for the treatment of atherosclerotic coronary lesions. 

The first patients in the study were enrolled by Professor Ian Meredith, primary investigator and director of MonashHeart, at Monash Medical Centre in Melbourne, Australia. The study will enroll up to 30 patients.

"By virtue of its unique design properties, incorporating thinner struts and enabling greater stent expansion while maintaining radial strength, this fully resorbable scaffold technology may potentially overcome a number of limitations with first generation absorbable scaffolds," said Professor Meredith.

The resorbable polymer scaffold incorporates several key design elements from the Boston Scientific SYNERGY™ Stent System, including a resorbable polymer and an ultrathin everolimus coating which is applied abluminally (on the exterior) to the scaffold. It also features a delivery system built with Boston Scientific expertise designed to facilitate improved acute performance.

"We are taking the best of our SYNERGY stent and applying it to our new, fully resorbable scaffold technology," said Kevin Ballinger, president, Interventional Cardiology, Boston Scientific. "We continue to invest in meaningful innovations designed to provide better outcomes for patients with coronary artery disease."

The Boston Scientific fully resorbable scaffold technology is under development and is not available for sale.  The SYNERGY Stent is an investigational device in the U.S. and Japan, and is not available for sale in those countries. The SYNERGY Stent has CE mark approval and is available for sale in countries where CE mark is accepted. 

About Boston Scientific Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.

Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our products, our business plans, clinical trials, and product performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. 

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACTS Media: Ryan Davenport Global Media Relations Boston Scientific Corporation 763-494-2664 (office) media@bsci.com 

Investors: Susie Lisa, CFA Investor Relations Boston Scientific Corporation (508) 683-5565 (office) investor_relations@bsci.com

SOURCE Boston Scientific



RELATED LINKS

http://www.bostonscientific.com